Clinical Trial

Gut Peptides and Bone Remodeling in Children With Neuromuscular Disorders

Terminated
View on ClinicalTrials.gov →
Why the trial stopped
Terminated since further recruitment proved difficult
Summary
Both GIP and GLP-2 reduce bone resorption (measured as CTX) in healthy adult individuals. In this study, we will investigate whether GIP and GLP-2 reduce CTX in children with spinal muscular atrophy, duchenne muscular dystrophy, or cerebral palsy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-19.
Status change: Recruiting → Terminated 2026-04-13
Trial Details
NCT Number NCT07254988
Lead Sponsor University of Copenhagen
Conditions Spinal Muscular Atrophy (SMA), Cerebral Palsy (CP), Duchenne Muscular Dystrophy (DMD)
Enrollment 3 participants
Start Date 2023-03-24
Primary Completion 2025-12-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-16